Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS evidence guidance

This article was originally published in The Gray Sheet

Executive Summary

Draft document focusing on clinical effectiveness thresholds needed to meet agency's standard for "reasonable and necessary" should "be out sometime this year" and will "describe what type of evidence we really are looking for," Ronald Dei Cas, MD, medical officer, Coverage & Analysis Group, states at the Fourth National Forum on Biomedical Imaging in Oncology in Bethesda, Md. Feb. 6. This spring, CMS also hopes to release its final reg on the beneficiary appeals process, allowing Medicare beneficiaries to challenge coverage policies directly. CMS' proposed rule was criticized by the House Ways & Means Committee and AdvaMed (1"The Gray Sheet" Oct. 28, 2002, p. 13)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT017860

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel